Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:amendedBy |
genetically engineered
|
| gptkbp:antigen |
gptkb:CD22
|
| gptkbp:cellType |
allogeneic T cells
|
| gptkbp:clinicalTrialPhase |
gptkb:United_States
gptkb:NCT04150497 Phase 1 |
| gptkbp:developedBy |
gptkb:Cellectis
|
| gptkbp:geneEditingTechnology |
gptkb:TALEN
|
| https://www.w3.org/2000/01/rdf-schema#label |
UCART22
|
| gptkbp:indication |
gptkb:B-cell_non-Hodgkin_lymphoma
B-cell acute lymphoblastic leukemia |
| gptkbp:manufacturer |
off-the-shelf
|
| gptkbp:mechanismOfAction |
redirects T cells to kill CD22-expressing cancer cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sponsor |
gptkb:Cellectis
|
| gptkbp:bfsParent |
gptkb:Cellectis
|
| gptkbp:bfsLayer |
7
|